Newly Diagnosed Papillary Craniopharyngioma With BRAF V600E Mutation Treated With Single-Agent Selective BRAF Inhibitor Dabrafenib: A Case Report

Oncotarget - United States
doi 10.18632/oncotarget.27203
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

Impact Journals, LLC

Related search

Redifferentiation of Iodine-Refractory BRAF V600e-Mutant Metastatic Papillary Thyroid Cancer With Dabrafenib

Clinical Cancer Research
Cancer ResearchOncology
2014English

Granulomatosis With Polyangiitis in a Patient Treated With Dabrafenib and Trametinib for BRAF V600E Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Small Molecules Against B-Raf (BRAF) Val600Glu (V600E) Single Mutation

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2015English

Targeted Treatment of Papillary Craniopharyngiomas Harboring BRAF V600E Mutations

Cancer
Cancer ResearchOncology
2019English

BRAF V600E Mutation in Hairy Cell Leukaemia a Single Center Descriptive Cross Sectional Study

Hematology & Transfusion International Journal
2017English

Recurrent Papillary Craniopharyngioma With BRAFV600E Mutation Treated With Neoadjuvant-Targeted Therapy

Acta Neurochirurgica
SurgeryNeurology
2017English

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Clinical Cancer Research
Cancer ResearchOncology
2014English

The BRAF V600E Mutation Is a Predictor of the Effect of Radioiodine Therapy in Papillary Thyroid Cancer

Journal of Cancer
Oncology
2020English

Papillary Craniopharyngioma in a Young Child: The Importance of BRAF Mutational Testing

Canadian Journal of Neurological Sciences
MedicineNeurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy